lonvo-z heads to FDA with Phase 3 HAE data as ATTR program recovers from a clinical hold and liver-toxicity death — approval timing determines which program carries the stock

Bull

FDA accepts the BLA and grants approval, enabling a H1 2027 U.S. commercial launch backed by compelling Phase 3 efficacy — 87% reduction in monthly attack rate, 62% attack-free and therapy-free at six months, and a clean Grade 1-2 safety profile with no serious adverse events in the lonvo-z arm. Approval would validate in vivo CRISPR gene editing as a commercial modality, provide a revenue base that reduces dilution risk, and reframe the ATTR clinical hold as a manageable setback rather than an existential threat.

Bear

The FDA raises concerns about the durability of effect beyond six months, manufacturing or CMC requirements for the gene-edited biologic, or requires additional safety data given the liver toxicity signals seen in the nex-z ATTR program — potentially triggering a Complete Response Letter or a labeling dispute that delays launch. The most likely failure modes are a CMC deficiency in the rolling BLA, a request for longer-term follow-up data to characterize durability of the kallikrein reduction, or a risk-mitigation requirement that limits prescriber access and undermines the launch trajectory.